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Abstract:  Problem  statement:  Multi-drug  resistant  Acinetobacter  bacterium  is  one  of  the  major 
causes of sepsis in ICUs in tertiary care hospitals in India. In this report we describe the antibiotic 
sensitivity patterns of Acinetobacter species isolated from blood over a one year period at a tertiary 
care hospital. Approach: We retrospectively analyzed the sensitivity pattern of Acinetobacter species 
isolated  from  blood  during  the  period  1/6/2010  to  31/5/2011.  Isolation  and  identification  were 
performed  using the best alert system and VITEK2 respectively. Sensitivities  were determined by 
Kirby Bauer disc diffusion and broth dilution using VITEK2 -AST cards. Results: The total number of 
Acinetobacter  species  isolated  during  the  study  period  was  72,  out  of  which  57  (79%)  were  A. 
baumanii, 7 (9.7%) were A. Iwofii and 3 (5.2%) were A. Junii. One each from A. calcoaceticus, A. 
ursingii and A. denitrificans were isolated. All of the baumanii isolates were sensitive to polymyxin B 
and 61.4% were sensitive to tigecycline. Only 25% of the isolates in baumanii group were sensitive to 
meropenem and imipenem. In the non-baumanii group however, 73% were sensitive to carbapenems. 
Conclusion: There is a very high incidence of resistance to most antibiotics, including carbapenems. 
All of the Acinetobacter isolates tested are sensitive to polymyxin B. Tigecycline is the only other drug 
with  reasonable  susceptibilities,  but  this  drug  is  not  recommended  for  primary  bacteriemias.  If 
Acinetobacter sepsis is suspected, empiric therapy with polymyxins, followed by de-escalation after 
sensitivity results are back, is advisable.  
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INTRODUCTION 
 
  Members  of  the  genus  Acinetobacter  are 
ubiquitous, free living, aerobic, Gram negative cocco-
bacilli that prefer a moist environment and can be easily 
obtained from  soil,  water, food and sewage (Dougari 
2011). 
  They  are  usually  considered  to  be  opportunistic 
pathogens  and  cause  nosocomial  infections  in 
hospitalized  patients  like  bacteremia,  pneumonia, 
meningitis and Urinary Tract Infection (UTI) (Towner, 
1997; Bergogne-Berezin et al., 1996). 
  Antimicrobial resistance among nosocomial isolates 
of  Acinetobacter  complicates  therapy  and  adversely 
affects  clinical  outcomes  and  treatment  costs 
(Brusselaers  et  al.,  2011;  Harris  et  al.,  1999).  The 
presence of resistance to most antibiotic classes requires 
the use of older and more toxic drugs like colistin for 
tackling Multi-Drug Resistant (MDR) strains (Fritsche et 
al., 2005). 
  We  analyzed  the  resistance  pattern  of 
Acinetobacter  species  grown  in  blood  culture  in 
patients during a one year period.  
 
MATERIALS AND METHODS 
 
  All isolates of Acinetobacter from blood over a 
period  of  1  year  (1/6/2010  to  31/5/2011)  were 
included  in  this  study.  Isolation  and  identification 
was performed using the Bac Talert and the VITEK 2 
machine  respectively.  Antibiotic  sensitivities  were 
determined by Kirby Bauer disc diffusion and broth 
dilution  using  VITEK2  and  AST  cards  and 
interpreted according to CLSI criteria. 
 
RESULTS 
 
  The  total  number  of  Acinetobacter  species  isolated 
during the study period was 72, out of which 57 (79%) 
were A. baumanii, 7 (9.7%) were A. Iwofii and 3 (5.2%) Am. J. Infect. Dis., 8 (1): 65-69, 2012 
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were  A.  junii.  One  each  from  A.  calcoaceticus,  A. 
haemolyticus, A. ursingii, A. denitrificans were isolated. 
One isolate did not belong to any of the above species.  
  All    the    isolates      in      the      Acinetobacter 
baumanii  group  were  sensitive  to      polymyxin    B 
(Table 1). 61.4%   were    sensitive   to    tigecycline. 
Sensitivities  of  imipenem,  meropenem  and 
doripenem were 24.55, 24.5 and 22.5% respectively. 
Only  12.5%  of  the  isolates  were  sensitive  to 
cefuroxime whereas for cefotaxime and ceftriaxone it 
was  12.2  and  10.5%  respectively.  Cefepime  and 
ceftazidime had marginally better sensitivities when 
compared  with  other  cephalosporins  (28%  each). 
Cefaperazone  +  sulbactam  combination  had  better 
sensitivities (33%) when compared to piperacillin + 
tazobactam (21%). 
  The  15  isolates  of  non  Baumanii  group  differed 
significantly from the Baumanii group, which had much 
greater sensitivities to all classes (Table 2). 
  
Table1: The antibiotic sensitivity pattern of 44 isolates of A. baumanii  
Antibiotic  Sensitive (%)  Intermediate (%) 
Polymyxin B  44 (100) 
Tigecycline  27 (61.4)  15(34.09) 
Cefaperazone/sulbactam  19(33.3)  4(7) 
Amikacin  14(24.5)  1(1.75) 
Ciprofloxacin  16(28) 
Cotrimoxazole  13(22.8) 
Piperacillin/tazobactam  12(21) 
Imipenem  14(24.5) 
Doripenem  13(22.8) 
Meropenem  14(24.5) 
Cefuroxime  7(12.2) 
Cefotaxime  7(12.2) 
Ceftriaxone  6(10.5) 
Cefepime  16(28) 
Ceftazidime  16(28) 
Aztreonam  8(14) 
 
Table 2: Antibiotic sensitivity pattern of 15 isolates of non baumanii group 
Antibiotic  Sensitive (%)  Intermediate (%) 
Polymyxin B  4 out of 4(100) 
Tigecycline  3out of 4(75) 
Cefaperazone+sulbactum  11(73) 
GM/Amikacin  12(80)  1(6.6) 
Cipro/Oflox  10(66.6) 
Cotrimoxazole  7(46.6)  1(6.6) 
Piperacillin+Tazobactam  11(73) 
Imipenem  11(73) 
Doripenem  11(73) 
Meropenem  11(73) 
Cefuroxime  7(46.6) 
Cefotaxime  7(46.6) 
Ceftriaxone  7(46.6) 
Cefepime  12(80) 
Ceftazidime  10(66.6) 
Aztreonam  7(46.6)  1(6.6) 
DISCUSSION 
 
  Acinetobacter  has  become  one  of  the  most 
important  causes  of  nosocomial  infections  (Gerner-
Smidt,  1995;  Gulati  et  al.,  1999)  and  causes 
considerable  mortality  as  it  has  acquired  many 
antibiotic  resistance  genes  including  the  novel 
carbapenemases.  It  is  an  opportunistic  pathogen 
associated with a wide spectrum of infections including 
nosocomial  pneumonia,  meningitis,  endocarditis,  skin 
and  soft  tissue  infections,  urinary  tract  infections, 
conjunctivitis,  burn  wound  infections  and  bacteremia 
(Bergogne-Berezin  and  Towner,  1996).  The  common 
form of resistance to carbapenems is mediated by lack of 
drug penetration (i.e., porin mutations and efflux pumps) 
and/or carbapenem hydrolyzing beta-lactamase enzymes 
including the Metallo-Betalactamases (MBL). Acquired 
MBLs are encoded  mobile  gene cassettes of organism 
and such strains are often resistant to different groups of 
antimicrobial  agents  with  transferable  properties  to 
various types of bacteria (Pitout et al., 2005). 
  Resistance rates to carbapenems vary significantly 
depending on the geographical region. In Greece, the 
proportion of imipenem-resistant A. baumanii isolates 
from patients hospitalized between 1996 and 2007 in 
tertiary care hospitals in several regions of the country 
rose from no resistance to 85% (ICUs), 60% (medical 
wards)  and  59%  (surgical  wards)
  GSSAR. 
Bloodstream isolates from the same dataset exhibited 
even  higher  resistance  rates.  The  prevalence  of 
imipenem  resistance  in  A.  baumanii  isolated  from  a 
burns unit of USA was found to be as high as 87% 
(2007) (Trottier et al., 2007). 
  Initial  Indian  studies  in  the  21st  century  showed 
that  Acinetobacter  species  were  fairly  sensitive.  For 
instance, Suri et al. (2000) demonstrated Acinetobacter 
in  patients  from  a  neurosurgical  unit  and  it  was 
sensitive  to  ciprofloxacin,  amikacin  cefotaxim  and 
ceftriaxone. Singh et al. (2002) showed Acinetobacter 
which  was  sensitive  to  amikacin.  Prashanth  and 
Badrinath  (2004)  from  JIPMER  Pondichery  isolated 
Acinetobacter  which  was  sensitive  to  amikacin  and 
ceftazidime. Isolates were resistant to ciprofloxacin and 
cefotaxime (Prashanth and Badrinath, 2004). Gladstone 
et  al.  (2005)  from  Vellore  reported  a  prevalence  of 
14%  carbapenem-resistant  Acinetobacter  spp., 
isolated from tracheal aspirates. 
  Banerjee  et  al.  (2005)  isolated  Acinetobacter 
from  different  body  fluids  which  has  good 
sensitivities for gentamycin. Prashanth and Badrinath 
(2006)  showed  gradually  increasing  resistance  of 
Acinetobacter. Gaur et al. (2008) noted resistance to 
meropenem  in  6.4%  of  Acinetobacter  species.  As Am. J. Infect. Dis., 8 (1): 65-69, 2012 
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recently as in 2010, one study from Ahmedabad showed 
few were carbapenem resistant (Patel et al., 2010). 
  However  there  are  now  several  Indian  studies 
showing  an  increased  prevalence  of  MDR 
Acinetobacter.  Our  study  shows  that  75%  of  our 
isolates were carbapenem resistant. This is concordant 
with recent reports from elsewhere in India. In 2009 a 
study  from  Rohtak  showed  that  the  resistance  of 
Acinetobacter  to  meropenem  had  increased  to  25.6% 
(Goel et al., 2009). In the same study the resistance to 
amikacin was 87.2% and ciprofloxacin was 89.7%. In 
Delhi,  India  (2006),  the  prevalence  of  carbapenem 
resistance  in  Acinetobacter  spp.  isolated  from 
different clinical samples was found to be almost 35%. 
Sinha  et  al.  (2007),  but  the  latest  studies  show 
resistance  to  carbapenem  is  seen  in  up  to  89%  of 
isolates (Jaggi et al., 2011). In our study the level of 
carbapenem resistance was very high in the Baumanii 
group. Karthika et al. (2009) in their study showed the 
presence  of  bla  IMP1  carbapenemase  genes  in  South 
Indian  population.  Though  bla  VIM-2  is  the  most 
common carbapenemases seen in other parts of world 
(Yum  et  al.,  2002;  Poirel  et  al.,  2000;  Walsh  et  al., 
2005), it was surprisingly absent in their study, though 
bla IMP1 gene was seen in 42% of isolates (Karthika et 
al.,  2009).  Our  study  showed  100%  sensitivity  to 
polymyxin.  Tigecycline  too  retained  activity  against 
MDR  isolates,  although  it  is  not  recommended  for 
primary bacteremias. However there have been reports 
of  polymyxin  resistant  Acinetobacter  from  Greece, 
Slovakia and other parts of Europe (Gales et al., 2006; 
Souli  et  al.,  2006).  Polymyxin  resistance  has  been 
reported from South Korea and the rates of resistance 
is  alarming,  18.1  and  27.9%  for  polymyxin  B  and 
colistin respectively (Ko et al., 2007). Recently there 
has  been  an  alarming  study  from  Chandigarh  where 
3.5% of all strains and 16% of carbapenem resistant 
strains were resistant to polymyxin B and tigecycline
 
(Taneja et al., 2011).  
  The antibiotic sensitivity pattern of non Baumanii 
group differed significantly from Baumanii group. Most 
of the isolates were sensitive to carbapenems and BL+ 
BLI combinations (73%). 
  The strength of our study is that only blood isolates 
were  analysed,  as  samples  from  other  sites  may 
represent colonization and may not reuire therapy. The 
polymyxin  group  remains  the  only  option  as  an 
empirical  therapy  if  Acinetobacter  bacteremia  is 
suspected,  as  it  showed  100%  sensitivities  to  MDR 
Acinetobacter.  Though  tigecycline  showed  good 
antibiotic  sensitivity  in  our  study,  it  is  not 
recommended for primary bacteremia due to low blood 
levels resulting inclinical failures. 
CONCLUSION 
 
  There was a very high incidence of resistance to 
most  antibiotic  classes,  including  carbapenems,  in 
Acinetobacter blood isolates in our center. All of the 
resistant isolates were however sensitive to polymyxin 
B. Tigecycline was the only other drug with reasonable 
susceptibilities.  If  Acinetobacter  bacteremia  is 
suspected, empiric therapy with the polymyxin group, 
followed  by  de-escalation  after  sensitivity  results  are 
back, is advisable. 
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